Methods And Compositions For Administering A Specific Wavelength Phototherapy

1 . A method delivering a dose of electromagnetic radiation (EMR) to an object, comprising the steps of:

covering the object with a composition which selectively allows passage of EMR of one or more predetermined wavelengths, while excluding other wavelengths; and

exposing said object to a light source that includes EMR of a spectrum that includes said one or more predetermined wavelengths.

2 . The method of claim 1 , further comprising the step of stopping the exposure of the object to the light source when the object has received a predetermined amount of EMR at the one or more predetermined wavelengths.

3 . The method of claim 2 , wherein said step of stopping occurs after a predetermined time after the beginning of said step of exposure, further comprising the step of adjusting the concentration of said composition within a carrier material so as to only allow, within the predetermined time, said predetermined amount of EMR.

4 . The method of claim 2 , further comprising the step of providing a dosimeter that measures exposure to at least one of said one or more predetermined wavelengths, and that provides an indication when said object has received a predetermined amount of EMR at the measured wavelength or wavelengths; wherein the step of stopping the exposure occurs when the dosimeter provides said indication.

5 . The method of claim 4 , further comprising the step of covering the dosimeter with said composition.

6 . The method of claim 2 , wherein said composition comprises a photoactive molecule that changes its chemical structure after being exposed to a threshold level of EMR, such that it becomes opaque to at least one of the one or more predetermined wavelengths; and wherein the step of stopping the exposure occurs when said photoactive molecule thus changes its chemical structure.

7 . The method of claim 1 , wherein one of said one or more predetermined wavelengths is approximately 311 nm.

8 . The method of claim 1 , wherein one of said one or more predetermined wavelengths is approximately 308 nm.

9 . The method of claim 1 , wherein said composition comprises a first composition that preferentially blocks EMR below one of said one or more predetermined wavelengths, and a second composition that preferentially blocks EMR above said one of said one or more predetermined wavelengths.

10 . The method of claim 1 , wherein said composition comprises one or more active photocream ingredients selected from the group consisting of avobenzone, cinoxate, dioxybenzone, Ecamsule, ensulizole, Escalol 507, Escalol 567, Eusolex 4360, Eusolex 6007, Eusolex 6300, Eusolex 8020, homosalate, meradimate, Mexenon, octocrylene, octinoxate, octisalate, oxybenzone, padimate 0, Parsol 1789, Parsol MCX, sulisobenzone, and trolamine salicylate.

11 . The method of claim 1 , wherein said composition comprises one or more components selected from the group consisting of scytonemin, mycosporine, mycosporine-glycine:valine, mycosporine-glycine, anthocyanidin, asterina, dihydroflavonol, flavone, flavanol, gadusol, isoflavone, nostoc commune E335, palythene, palythenic acid, palythine, palythinol, porphyra, and shinorine.

12 . The method of claim 1 , wherein said step of exposing comprises delivering of light that has been amplified at one or more particular wavelengths.

13 . The method of claim 12 , wherein said amplification comprises fluorescence emission, and said one or more particular wavelengths are said one or more predefined wavelengths.

14 . The method of claim 1 , wherein the object is a plant sensitive to at least one of said one or more particular wavelengths.

15 . The method of claim 1 , wherein the object is a polymer which is capable of being cured by exposure to EMR at said one or more predetermined wavelengths.

16 . The method of claim 1 , wherein the object is the skin of a human subject, the composition is a band-pass topical photocream, the step of covering the object comprises application of said photocream, and the one or more predetermined wavelengths are ultraviolet wavelengths selected to provide phototherapy to the subject, and wherein the step of exposing comprises exposing the skin to sunlight or an artificial ultraviolet light source.

17 . The method of claim 16 , wherein the phototherapy is for treatment of a dermatological condition selected from the group consisting of vitiligo, psoriasis, atopic dermatitis, grey hair, and skin infection.

18 . The method of claim 16 , wherein the phototherapy is for wound healing, varicose vein therapy, androgenetic alopecia, or other forms of alopecia.

19 . The method of claim 16 , wherein the phototherapy is for treatment of rickets, osteomalacia, osteoporosis, other forms of impaired bone mineralization, or low blood calcidiol.

20 . A composition comprising:

a cosmetic-grade carrier lotion suitable for application to human skin; and

a first composition, suitable for application to human skin, that preferentially blocks EMR below one of said one or more predetermined wavelengths, and a second composition, suitable for application to human skin, that preferentially blocks EMR above said one of said one or more predetermined wavelengths, wherein the first component and the second component are selected, and included within the composition at a mutual ratio so as to produce an absorption spectrum with a valley at approximately 306 nm to approximately 320 nm, and wherein the concentration of the first component and the second component in the carrier lotion is between about 0.10% (w/w) and about 5% (w/w).

21 . The composition of claim 20 , wherein said valley is between about 306 nm and about 310 nm.

22 . The composition of claim 21 , wherein said valley is approximately 308 nm.

23 . The composition of claim 20 , wherein said valley is approximately 311 nm.

24 . The composition of claim 20 , wherein a first component and a second component, are each selected from the group consisting of hesperidin (CAS #520-26-3), vinblastine (CAS #865-21-4), acteoside (CAS #61276-17-3), acacetin 7-O-rutinoside (CAS #480-36-4), phytoene (CAS #13920-14-4), poncirin (CAS #14941-08-3), gambogic acid (CAS #2752-65-0), chaetoglobosin (CAS #50335-03-0), poliumoside (CAS #94079-81-9), sitosteroline (CAS #474-58-8), naringin (CAS #10236-47-2), pentagalloyl glucose (CAS #14937-32-7), amentoflavone (CAS #1617-53-4), tetrandrine (CAS #518-34-3), isoacteoside (CAS #61303-13-7), (-)-phaeanthine (CAS #1263-79-2), garcinol (CAS #78824-30-3), salvianolic acid B (CAS #121521-90-2), docetaxel (CAS #114977-28-5), ecdysterone (CAS #5289-74-7), glycyrrhizic acid monosodium salt (CAS #11052-19-0), kaempferol (CAS #81992-85-0), paclitaxel (CAS #33069-62-4), silymarin (CAS #22888-70-6), isoacteoside (CAS #61303-13-7), linarin (CAS #480-36-4), pectolinarin (CAS #28978-02-1), rutin (CAS #153-18-4), kaempferol-3-O-rutinoside (CAS #17650-84-9), diosmin (CAS #520-27-4), rhoifolin (CAS #17306-46-6), avobenzone (CAS #70356-09-1), alpha glucosyl hesperidin (CAS #161713-86-6), and diethylamino hydroxybenzoyl hexyl benzoate (CAS #302776-68-7), wherein the first component and the second component are selected, and included within the composition at a mutual ratio so as to produce an absorption spectrum with a valley at approximately 306 nm to approximately 320 nm, and wherein the concentration of the first component and the second component in the carrier lotion is between about 0.10% (w/w) and about 5% (w/w).

25 . The composition of claim 24 , wherein the first component is alpha glucosyl hesperidin and the second component is diethylamino hydroxybenzoyl hexyl benzoate.

26 . The composition of claim 25 , wherein said mutual ratio is between about 7:2 and about 9:2 of the first component to the second component.

27 . The composition of claim 26 , wherein said mutual ratio is about 4:1 of the first component to the second component.

28 . The composition of claim 25 , wherein said mutual ratio is between about 4:3 and about 5:3 of the first component to the second component.

29 . The composition of claim 28 , wherein said mutual ratio is about 3:2 of the first component to the second component.

30 . The composition of claim 24 , wherein the first component is Silymarin and the second component is diethylamino hydroxybenzoyl hexyl benzoate.

31 . The composition of claim 30 , wherein said mutual ratio of the first component to the second component is within a range selected from the group consisting of about 5:9 and about 7:9 and about 1:3 and about 7:15.

32 . The composition of claim 20 , further comprising a photoactive molecule that changes its chemical structure after being exposed to a threshold level of EMR, such that it becomes opaque to one or more wavelength within the region of approximately 306 nm to approximately 320 nm.

33 . A kit comprising the composition of claim 20 , and further comprising a dosimeter that measures exposure to the one of said one or more predetermined wavelengths, and that provides an indication when said object has received a predetermined amount of EMR at the one of said one or more predetermined wavelengths.